ClinicalTrials.gg
Not yet recruitingNCT07837518Updated Sep 25, 2026

Knowledge of Inborn Errors of Immunity Among Pediatric Physicians

An observational study in Primary Immunodeficiency Diseases, sponsored by Assiut University. Not yet recruiting. Open to participants aged 24 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Assiut University · Observational

Updated Sep 25, 2026Primary outcomes revisedGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
347
Ages
24 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to assess the level of knowledge regarding inborn errors of immunity among pediatric physicians working in Assiut Governorate, Egypt.

Read the detailed description

Inborn errors of immunity (IEI) are heterogeneous disorders that can present with recurrent, severe, or unusual infections, autoimmunity, and other manifestations. Early recognition by pediatric physicians is important for timely diagnosis and management.

This observational study will use a self-administered electronic questionnaire to assess knowledge of clinical warning signs, general and specific signs of IEI, and treatment and immunization strategies among pediatric physicians in Assiut.

02

Conditions studied

  • Primary Immunodeficiency Diseases

Keywords

  • Inborn errors of immunity
  • Primary immunodeficiency
  • Pediatric physicians
  • Assiut
  • Knowledge assessment
03

In context

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

This study's planned enrollment of 347 is above the median of 137 across 77 observational studies indexed under Primary Immunodeficiency Diseases.

Browse Primary Immunodeficiency Diseases studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pediatric physicians working in participating hospitals in Assiut Governorate, Egypt.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Working as a pediatric physician in Assiut
  • Practicing pediatrics in a participating hospital
  • Willing to participate and able to complete the electronic questionnaire
  • Providing

Exclusion criteria

Exclusion Criteria:

  • - Refusal to participate
  • Inadequate or substantially incomplete questionnaire response
  • Not currently practicing pediatrics
  • Participation in questionnaire development or validation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
347 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Pediatric physicians

    Pediatric physicians working in Assiut who will complete a self-administered electronic questionnaire assessing knowledge of inborn errors of immunity.

06

What researchers measure

Primary outcomes

  1. Overall knowledge score regarding inborn errors of immunity

    Mean percentage score of correct answers on the knowledge questionnaire regarding inborn errors of immunity (maximum score expressed as percentage) Score ranges from 0 to 100%, with higher scores indicating better knowledge.

    Time frame: Baseline

Secondary outcomes

  1. Domain-Specific Knowledge Scores

    Separate percentage scores for four domains: 1) Warning signs in children (4 questions) and adults (2 questions), 2) General signs of IEI (5 questions), 3) Specific signs of IEI (9 questions), 4) Treatment strategies and immunization (5 questions) Score ranges from 0 to 100%, with higher scores indicating better knowledge.

    Time frame: Baseline

  2. Knowledge scores according to professional and educational characteristics

    Mean overall knowledge scores stratified by years of experience, educational level, hospital affiliation type, previous training in pediatric immunology, and daily case flow.Score ranges from 0 to 100%, with higher scores indicating better knowledge.

    Time frame: Baseline

  3. Mean knowledge scores by hospital

    Comparison of mean overall knowledge scores across participating hospitals in Assiut Governorate to identify hospitals with greatest knowledge gaps requiring priority targeted educational and training activities. Interpreted in relation to number of participating physicians per hospital.Score ranges from 0 to 100%, with higher scores indicating better knowledge.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 23, 2026
StartEst.
Sep 20, 2026
Primary completionEst.
Sep 20, 2027
CompletionEst.
Mar 10, 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionOverall knowledge score regarding inborn errors of immunity: how it is measured was reworded
Sep 25, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionDomain-Specific Knowledge Scores: how it is measured was reworded
  • DescriptionKnowledge scores according to professional and educational characteristics: how it is measured was reworded
  • DescriptionMean knowledge scores by hospital: how it is measured was reworded
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionOverall knowledge score regarding inborn errors of immunity: how it is measured was reworded
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionDomain-Specific Knowledge Scores: how it is measured was reworded
    • DescriptionKnowledge scores according to professional and educational characteristics: how it is measured was reworded
    • DescriptionMean knowledge scores by hospital: how it is measured was reworded

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07837518
Lead sponsor
Assiut University
Responsible party
Loay Salah Sodky (Resident Physician, Assiut University) — Principal investigator
First posted
Sep 23, 2026
Start date
Sep 20, 2026 (estimated)
Primary completion
Sep 20, 2027 (estimated)
Completion
Mar 10, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Loay s sedky, Resident
Contact
Loay.17289948@med.aun.edu.eg
+20 12 02936248
Mustafa M Embaby, prof
study chair · Pediatrics Hematology department Faculty of Medicine, Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion